Form 4: Denali CMO Exercises Stock Options

Denali Therapeutics' Chief Medical Officer, Carole Ho, exercised 44,655 stock options at $0.68 per share, increasing her direct common stock holdings.

Summary

• Carole Ho, Chief Medical Officer of Denali Therapeutics Inc. (DNLI), exercised stock options.
• On August 5, 2025, she exercised options to acquire 44,655 shares of common stock.
• The exercise price for these shares was $0.68 per share.
• Following this transaction, her direct beneficial ownership of common stock increased to 220,328 shares, which includes 134,030 unvested Restricted Stock Units (RSUs).
• She also holds indirect beneficial ownership of 183,219 shares through the Rohatgi-Ho Family 2009 Revocable Trust and 25,000 shares through The Rohatgi-Ho Irrevocable GST Trust.
• The exercised options were part of a grant where 50% vested on March 3, 2021, and the remaining 50% are contingent on Denali's common stock closing at or above $80.00 per share on NASDAQ for 90 consecutive trading days.

Sentiment

Score: 7

Explanation: The exercise of stock options by a key executive, increasing their direct ownership, generally signals confidence in the company's future prospects. The low exercise price also suggests a strong incentive for the executive to see the stock price appreciate.

Positives

• Chief Medical Officer Carole Ho increased her direct ownership in the company by exercising stock options, which can signal confidence in future performance.
• The exercise price of $0.68 per share is significantly low, indicating a substantial potential gain if the stock price is higher.

Negatives

• No direct negatives identified from this specific transaction, as it represents an acquisition of shares by an insider.

Risks

• The vesting of 50% of the stock options is contingent on Denali Therapeutics' common stock reaching or exceeding $80.00 per share on NASDAQ for 90 consecutive trading days, posing a performance-based risk to full option realization.

Future Outlook

The future outlook for a portion of the Chief Medical Officer's equity compensation is tied to the company's stock price reaching a significant milestone of $80.00 per share for 90 consecutive trading days, indicating a long-term performance incentive.

Management Comments

• No direct management quotes are provided in this Form 4 filing.

Industry Context

This filing details an individual insider transaction and does not provide information directly related to broader industry trends or competitor analysis.

Comparison to Industry Standards

• Not applicable as this filing pertains to an individual insider transaction and does not contain information for industry-wide comparisons.

Related Party Transactions

• Indirect beneficial ownership of shares held by the Rohatgi-Ho Family 2009 Revocable Trust, for which the Reporting Person serves as trustee.
• Indirect beneficial ownership of shares held by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through increased equity ownership.

Next Steps

• Achievement of Denali Therapeutics' common stock closing price at or above $80.00 per share on NASDAQ for 90 consecutive trading days for the remaining 50% of stock options to vest.

Key Dates

Recommendation

The exercise of stock options by a Chief Medical Officer is a positive signal of insider confidence and alignment with shareholder interests. However, this routine transaction alone does not provide sufficient new fundamental information to warrant a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate for existing investors.

Keywords

Denali Therapeutics, DNLI, Stock Option Exercise, Insider Transaction, Form 4, Chief Medical Officer, Carole Ho, Equity Ownership